Profile data is unavailable for this security.
About the company
Nykode Therapeutics ASA is a Norway-based clinical-stage biopharmaceutical platform company dedicated to the discovery and development of vaccines and immunotherapies for cancer and infectious diseases. Nykode uses its vaccine technology platform to generate therapeutics in disease indications with unmet medical need. The Company develops next generation vaccines for clinical use, based on a deep understanding of immunological principles. Nykode Therapeutics’ main product candidates are VB10.16 and VB10.NEO. VB10.16 is a therapeutic cancer vaccine against HPV16-related cancers. VB10. NEO is a therapeutic cancer neoantigen vaccine. The Company also has two universal COVID-19 vaccine candidates in development.
- Revenue in NOK (TTM)64.20m
- Net income in NOK-104.30m
- Incorporated2007
- Employees62.00
- LocationNykode Therapeutics ASAOslo Science Park, Gaustadalleen 21OSLO 0349NorwayNOR
- Phone+47 22958193
- Fax+47 22604427
- Websitehttps://nykode.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Lytix Biopharma AS | 0.00 | -59.98m | 721.48m | 6.00 | -- | 10.17 | -- | -- | -0.8794 | -0.8794 | 0.00 | 0.9046 | 0.00 | -- | -- | -- | -52.60 | -55.33 | -69.45 | -65.46 | -- | -- | -- | -761.70 | -- | -- | 0.0344 | -- | -100.00 | -- | 36.37 | -- | -- | -- |
| Nanoform Finland Oyj | 33.31m | -245.36m | 731.80m | 173.00 | -- | 1.46 | -- | 21.97 | -0.2613 | -0.2613 | 0.0354 | 0.5203 | 0.0442 | 80.07 | 9.22 | 16,328.73 | -32.55 | -26.72 | -36.27 | -29.06 | -441.87 | -539.46 | -736.69 | -918.61 | 4.30 | -- | 0.1281 | -- | 8.22 | 124.15 | -12.87 | -- | -1.62 | -- |
| Hamlet BioPharma AB | 0.00 | -60.09m | 759.57m | 6.00 | -- | 17.73 | -- | -- | -0.3157 | -0.3157 | 0.00 | 0.2927 | 0.00 | -- | -- | 0.00 | -95.68 | -78.53 | -104.48 | -91.76 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -30.70 | -- | -- | -- |
| Oncopeptides AB | 66.50m | -284.63m | 781.74m | 75.00 | -- | 112.36 | -- | 11.76 | -1.20 | -1.20 | 0.2798 | 0.0253 | 0.2359 | 0.2049 | 1.79 | 782,225.00 | -100.98 | -148.24 | -125.09 | -215.27 | 97.88 | -- | -428.01 | -2,013.60 | 3.27 | -12.10 | 0.9507 | -- | -10.14 | -- | -14.25 | -- | -7.14 | -- |
| Curasight A/S | -67.41m | -72.79m | 1.06bn | 4.00 | -- | 40.04 | -- | -- | -1.13 | -1.13 | -1.07 | 0.3809 | -1.52 | -- | -- | -11,171,250.00 | -163.63 | -37.34 | -313.58 | -40.89 | -- | -- | -- | -- | -- | -16.54 | 0.00 | -- | -27.21 | -- | -40.76 | -- | -- | -- |
| XSpray Pharma AB (publ) | 0.00 | -229.99m | 1.20bn | 26.00 | -- | 1.77 | -- | -- | -5.96 | -5.96 | 0.00 | 15.37 | 0.00 | -- | -- | 0.00 | -29.09 | -23.48 | -30.93 | -25.08 | -- | -- | -- | -- | 5.93 | -18.44 | 0.1883 | -- | -- | -- | -58.92 | -- | -14.46 | -- |
| Nykode Therapeutics ASA | 64.20m | -104.30m | 1.22bn | 62.00 | -- | 1.29 | -- | 18.95 | -0.3093 | -0.3093 | 0.194 | 2.88 | 0.0494 | -- | 1.91 | 461,874.80 | -8.03 | 2.32 | -8.66 | 2.60 | -- | -- | -162.46 | 8.51 | -- | -- | 0.0284 | -- | -32.73 | -- | -10.43 | -- | -1.35 | -- |
| Cantargia AB | 328.04m | 148.70m | 1.35bn | 23.00 | 10.06 | 4.26 | 8.84 | 4.11 | 0.5068 | 0.5068 | 1.33 | 1.20 | 1.41 | -- | 164.02 | 14,031,360.00 | 63.91 | -56.56 | 80.65 | -63.93 | -- | -- | 45.33 | -- | -- | 76.55 | 0.00 | -- | -- | -- | 42.27 | -- | -- | -- |
| Nightingale Health Oyj | 52.89m | -208.04m | 1.51bn | 100.00 | -- | 1.49 | -- | 28.62 | -0.3052 | -0.3052 | 0.0778 | 1.10 | 0.0568 | 0.9444 | 2.79 | 46,930.00 | -22.33 | -15.66 | -24.26 | -16.95 | 75.39 | 75.21 | -393.39 | -447.17 | 8.52 | -- | 0.0511 | -- | 7.69 | 21.38 | -5.71 | -- | -12.69 | -- |
| Solar Foods Oyj | 215.36k | -120.19m | 1.54bn | 57.00 | -- | 6.44 | -- | 7,162.09 | -0.433 | -0.433 | 0.0008 | 0.7115 | 0.0004 | -- | 0.0037 | 455.00 | -22.45 | -- | -27.05 | -- | 25,931.57 | -- | -55,808.37 | -- | -- | -7.03 | 0.5092 | -- | 275.15 | -- | -22.57 | -- | -- | -- |
| Intellego Technologies AB | 819.13m | 313.13m | 1.65bn | 65.00 | 4.75 | 2.33 | 4.81 | 2.01 | 9.81 | 9.81 | 25.91 | 20.01 | 1.28 | 10.59 | 2.32 | 12,432,400.00 | 49.11 | 17.13 | 61.64 | 23.87 | 70.97 | 58.82 | 38.23 | 21.32 | 4.11 | 5.35 | 0.0617 | -- | 42.25 | 222.71 | 14.78 | -- | -- | -- |
| Devyser Diagnostics AB | 258.02m | -26.78m | 1.77bn | 115.00 | -- | 4.88 | 1,189.55 | 6.86 | -1.52 | -1.52 | 14.66 | 20.48 | 0.5262 | 1.40 | 5.53 | 1,839,394.00 | -5.64 | -10.61 | -6.60 | -12.04 | 81.96 | 80.33 | -10.71 | -28.67 | 2.27 | -2.03 | 0.1312 | -- | 28.12 | 27.53 | -14.74 | -- | 52.54 | -- |
Data as of Feb 17 2026. Currency figures normalised to Nykode Therapeutics ASA's reporting currency: Norwegian Krone NOK
7.14%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Capital Research & Management Co. (World Investors)as of 10 Oct 2025 | 16.39m | 5.02% |
| DNB Asset Management ASas of 28 Nov 2025 | 3.19m | 0.98% |
| Storebrand Asset Management ASas of 30 Nov 2025 | 2.01m | 0.62% |
| Equinor Asset Management ASAas of 30 Jun 2025 | 822.60k | 0.25% |
| Alfred Berg Kapitalforvaltning ASas of 30 Jan 2026 | 607.00k | 0.19% |
| Andbank Wealth Management SGIIC SAUas of 30 Jun 2025 | 230.43k | 0.07% |
| Danske Bank A/S (Investment Management)as of 31 Jan 2026 | 37.94k | 0.01% |
| Handelsbanken Fonder ABas of 31 Jan 2025 | 20.15k | 0.01% |
| SSgA Funds Management, Inc.as of 05 Feb 2026 | 9.20k | 0.00% |
| BlackRock Investment Management (UK) Ltd.as of 31 Jul 2025 | 0.00 | 0.00% |
More ▼
Data from 30 Jun 2025 - 11 Feb 2026Source: FactSet Research Systems Inc.
